allogeneic sibling umbilical cord blood

Allogeneic sibling umbilical cord blood is an investigational cellular therapy consisting of hematopoietic stem cells and other cellular components derived from the umbilical cord blood of HLA-matched or partially HLA-matched siblings. Primarily developed and studied at Duke University, this therapy is administered via a single intravenous infusion without the need for prior conditioning or immunosuppression. Its mechanism of action is hypothesized to involve immunomodulatory effects mediated through paracrine signaling, which may promote neural repair and improve motor function in patients with neurological conditions such as cerebral palsy. Clinical trials, including those under IND 16615, have demonstrated that the therapy is well-tolerated in pediatric populations.

Other names

sibling umbilical cord bloodallogeneic sibling CBsibling CB